By Jason Derry —

Novogen Ltd. and Chattem, Inc. have reached a settlement, ending the legal action regarding isoflavone-containing health supplements.  Novogen filed suit against Chattem, alleging that
certain Chattem menopause products infringed two
of Novogen’s U.S. patents – in particular, U.S. Patent Nos. 6,562,380 and 6,987,098.

Novogen has previously enforced its patents against several other health supplement providers in the U.S. and Canada.  The details of the settlement have not been made public.  Novagen’s press release on the settlement can be found here.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.